LENZ Therapeutics, Inc. (LENZ)
3.01
-0.45
(-13.01%)
USD |
NASDAQ |
Nov 05, 16:00
3.18
+0.17
(+5.65%)
After-Hours: 06:15
LENZ Therapeutics SG&A Expense (TTM) : 159.82M for Sept. 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 159.82M |
| June 30, 2026 | 151.57M |
| March 31, 2026 | 124.98M |
| December 31, 2025 | 91.14M |
| September 30, 2025 | 60.86M |
| June 30, 2025 | 39.76M |
| March 31, 2025 | 34.37M |
| December 31, 2024 | 28.81M |
| September 30, 2024 | 34.05M |
| June 30, 2024 | 30.42M |
| March 31, 2024 | 25.33M |
| December 31, 2023 | 22.07M |
| September 30, 2023 | 15.76M |
| June 30, 2023 | 20.75M |
| Date | Value |
|---|---|
| March 31, 2023 | 27.43M |
| December 31, 2022 | 32.85M |
| September 30, 2022 | 32.30M |
| June 30, 2022 | 30.36M |
| March 31, 2022 | 26.23M |
| December 31, 2021 | 22.51M |
| September 30, 2021 | 16.71M |
| June 30, 2021 | 12.24M |
| March 31, 2021 | 8.247M |
| December 31, 2020 | 4.377M |
| September 30, 2020 | 2.444M |
| June 30, 2020 | 0.99M |
| March 31, 2020 | 0.121M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Impact BioMedical, Inc. | 0.349M |
| EyePoint, Inc. | 55.41M |
| Ligand Pharmaceuticals, Inc. | 147.60M |
| Enveric Biosciences, Inc. | 6.099M |
| Indivior Pharmaceuticals, Inc. (DELISTED) | 555.00M |